These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
521 related articles for article (PubMed ID: 34418708)
1. Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association? Introna A; Caputo F; Santoro C; Guerra T; Ucci M; Mezzapesa DM; Trojano M Clin Neurol Neurosurg; 2021 Sep; 208():106887. PubMed ID: 34418708 [TBL] [Abstract][Full Text] [Related]
2. Exploring the adverse events of Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, and Johnson and Johnson COVID-19 vaccination on Guillain-Barré Syndrome. Meo SA; Shaikh N; Abukhalaf FA; Meo AS Sci Rep; 2024 Aug; 14(1):18767. PubMed ID: 39138276 [TBL] [Abstract][Full Text] [Related]
3. Associations of Guillain-Barré syndrome with coronavirus disease 2019 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database. Kim JE; Park J; Min YG; Hong YH; Song TJ J Peripher Nerv Syst; 2022 Sep; 27(3):206-214. PubMed ID: 35751472 [TBL] [Abstract][Full Text] [Related]
4. Effects of COVID-19 vaccine type on Guillain-Barré syndrome: Two cases and a literature review. Lee HY; Lien WC Hum Vaccin Immunother; 2023 Dec; 19(1):2171231. PubMed ID: 36919452 [TBL] [Abstract][Full Text] [Related]
5. Guillain-Barré syndrome after COVID-19 vaccines: A Tunisian case series. Berrim K; Lakhoua G; Zaiem A; Charfi O; Aouinti I; Kastalli S; Daghfous R; El Aidli S Br J Clin Pharmacol; 2023 Feb; 89(2):574-578. PubMed ID: 36398559 [TBL] [Abstract][Full Text] [Related]
6. COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database. Keh RYS; Scanlon S; Datta-Nemdharry P; Donegan K; Cavanagh S; Foster M; Skelland D; Palmer J; Machado PM; Keddie S; Carr AS; Lunn MP; Brain; 2023 Feb; 146(2):739-748. PubMed ID: 35180300 [TBL] [Abstract][Full Text] [Related]
7. Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature. Min YG; Ju W; Ha YE; Ban JJ; Lee SA; Sung JJ; Shin JY J Neuroimmunol; 2021 Oct; 359():577691. PubMed ID: 34416410 [TBL] [Abstract][Full Text] [Related]
8. Guillain-Barré syndrome after COVID-19 vaccination: A systematic review and analysis of case reports. Abuawwad MT; Taha MJJ; Taha AJ; Kozaa YA; Falah O; Abuawwad IT; Hammad EM; Mahmoud AA; Aladawi M; Serhan HA Clin Neurol Neurosurg; 2024 Mar; 238():108183. PubMed ID: 38401232 [TBL] [Abstract][Full Text] [Related]
9. Guillain-Barré syndrome after COVID-19 vaccination: report of two cases from Vietnam. Hai PD; Phuong LL; Tot NH; Anh NLP; Tung ND; Quan NH J Infect Dev Ctries; 2022 Nov; 16(11):1703-1705. PubMed ID: 36449641 [TBL] [Abstract][Full Text] [Related]
12. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine. Nasuelli NA; De Marchi F; Cecchin M; De Paoli I; Onorato S; Pettinaroli R; Savoini G; Godi L Neurol Sci; 2021 Nov; 42(11):4747-4749. PubMed ID: 34272622 [TBL] [Abstract][Full Text] [Related]
13. Clinical Variant of Guillain-Barre Syndrome With Prominent Facial Diplegia After AstraZeneca Coronavirus Disease 2019 Vaccine. Badoiu A; Moranne O; Coudray S; Ion IM J Clin Neuromuscul Dis; 2021 Dec; 23(2):115-116. PubMed ID: 34808658 [No Abstract] [Full Text] [Related]
14. Risk of Guillain-Barré Syndrome Following COVID-19 Vaccines: A Nationwide Self-Controlled Case Series Study. Le Vu S; Bertrand M; Botton J; Jabagi MJ; Drouin J; Semenzato L; Weill A; Dray-Spira R; Zureik M Neurology; 2023 Nov; 101(21):e2094-e2102. PubMed ID: 37788935 [TBL] [Abstract][Full Text] [Related]
15. Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023. Jeong YD; Park S; Lee S; Jang W; Park J; Lee K; Lee J; Kang J; Udeh R; Rahmati M; Yeo SG; Smith L; Lee H; Yon DK Sci Rep; 2024 Oct; 14(1):24561. PubMed ID: 39427003 [TBL] [Abstract][Full Text] [Related]
16. AstraZeneca COVID-19 vaccine and Guillain- Barré Syndrome in Tasmania: A causal link? Oo WM; Giri P; de Souza A J Neuroimmunol; 2021 Nov; 360():577719. PubMed ID: 34560365 [TBL] [Abstract][Full Text] [Related]
17. Guillain-Barrè syndrome following COVID-19 vaccine mRNA-1273: a case report. Masuccio FG; Comi C; Solaro C Acta Neurol Belg; 2022 Oct; 122(5):1369-1371. PubMed ID: 34767184 [No Abstract] [Full Text] [Related]
18. Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine. García-Grimshaw M; Michel-Chávez A; Vera-Zertuche JM; Galnares-Olalde JA; Hernández-Vanegas LE; Figueroa-Cucurachi M; Paredes-Ceballos O; Reyes-Terán G; Carbajal-Sandoval G; Ceballos-Liceaga SE; Arauz A; Valdés-Ferrer SI Clin Immunol; 2021 Sep; 230():108818. PubMed ID: 34358692 [TBL] [Abstract][Full Text] [Related]
19. Post-marketing active surveillance of Guillain Barré Syndrome following COVID-19 vaccination in persons aged ≥12 years in Italy: A multi-database self-controlled case series study. Morciano C; Spila Alegiani S; Menniti Ippolito F; Belleudi V; Trifirò G; Zanoni G; Puccini A; Sapigni E; Mores N; Leoni O; Monaco G; Clagnan E; Zappetti C; Bovo E; Cutillo M; Da Cas R; Massari M PLoS One; 2024; 19(1):e0290879. PubMed ID: 38241309 [TBL] [Abstract][Full Text] [Related]
20. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis. Li X; Raventós B; Roel E; Pistillo A; Martinez-Hernandez E; Delmestri A; Reyes C; Strauss V; Prieto-Alhambra D; Burn E; Duarte-Salles T BMJ; 2022 Mar; 376():e068373. PubMed ID: 35296468 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]